文献速递免疫规划卫生政策与健康促进

ADVANCE数据库特征描述与适用性评估:用于百日咳疫苗接种覆盖率、获益与风险的多国研究

ADVANCE database characterisation and fit for purpose assessment for multi-country studies on the coverage, benefits and risks of pertussis vaccinations.
PubMed 文献 · Vaccine · 2020-02-12

ADVANCE联盟评估欧洲医疗数据库能否用于百日咳疫苗覆盖率、获益与风险研究。百日咳覆盖率估计与WHO报告相似,事件发生率在特征相同的数据库间量级和年龄分布可比。部分结局(持续哭闹、嗜睡)在仅限出院诊断的数据库中未被捕获。

要点

  • 特征相同的数据库间事件发生率量级和年龄分布可比。
  • 持续哭闹和嗜睡在仅限出院诊断的数据库中未被捕获。

核心结论

  • 数据库特征描述程序和工作流程可高效、透明、标准化地描述和验证电子医疗数据库,这些数据库可参与百日咳疫苗覆盖率、获益与风险研究。
  • 该方法已准备好用于其他疫苗/事件,为参与其他疫苗相关研究做好准备。

研究设计与样本

  • 使用开源Java-based(Jerboa)软件和R脚本对欧洲医疗数据库进行特征描述。
  • 九个数据库(初级保健、区域/国家记录链接)提供百日咳概念验证研究相关事件和疫苗数据。

主要发现

  • 七个数据库记录了疫苗剂量。
  • 百日咳覆盖率估计与WHO报告相似。
  • 特征相同的数据库间事件发生率量级和年龄分布可比。
  • 持续哭闹和嗜睡在仅限出院诊断的数据库中未被捕获。

关键数值与推荐

  • 七个数据库记录了疫苗剂量。
  • 九个数据库提供百日咳、肺炎、死亡、发热、惊厥、注射部位反应、低张力低反应发作、持续哭闹等事件数据。
  • 九个数据库提供无细胞百日咳疫苗和全细胞百日咳疫苗数据。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 持续哭闹和嗜睡在仅限出院诊断的数据库中未被捕获。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The public-private ADVANCE consortium (Accelerated development of vaccine benefit-risk collaboration in Europe) aimed to assess if electronic healthcare databases can provide fit-for purpose data for collaborative, distributed studies and monitoring of vaccine coverage, benefits and risks of vaccines. OBJECTIVE: To evaluate if European healthcare databases can be used to estimate vaccine coverage, benefit and/or risk using pertussis-containing vaccines as an example. METHODS: Characterisation was conducted using open-source Java-based (Jerboa) software and R scripts. We obtained: (i) The general characteristics of the database and data source (meta-data) and (ii) a detailed description of the database population (size, representatively of age/sex of national population, rounding of birth dates, delay between birth and database entry), vaccinations (number of vaccine doses, recording of doses, pattern of doses by age and coverage) and events of interest (diagnosis codes, incidence rates). A total of nine databases (primary care, regional/national record linkage) provided data on events (pertussis, pneumonia, death, fever, convulsions, injection site reactions, hypotonic hypo-responsive episode, persistent crying) and vaccines (acellular pertussis and whole cell pertussis) related to the pertussis proof of concept studies. RESULTS: The databases contained data for a total population of 44 million individuals. Seven databases had recorded doses of vaccines. The pertussis coverage estimates were similar to those reported by the World Health Organisation (WHO). Incidence rates of events were comparable in magnitude and age-distribution between databases with the same characteristics. Several conditions (persistent crying and somnolence) were not captured by the databases for which outcomes were restricted to hospital discharge diagnoses. CONCLUSION: The database characterisation programs and workflows allowed for an efficient, transparent and standardised description and verification of electronic healthcare databases which may participate in pertussis vaccine coverage, benefit and risk studies. This approach is ready to be used for other vaccines/events to create readiness for participation in other vaccine related studies.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sturkenboom M, Braeye T, van der Aa L, et al. ADVANCE database characterisation and fit for purpose assessment for multi-country studies on the coverage, benefits and risks of pertussis vaccinations. Vaccine. 2020. PMID: 32061385. doi:10.1016/j.vaccine.2020.01.100

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。